Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) EBT Margin (2016 - 2020)

KalVista Pharmaceuticals' EBT Margin history spans 7 years, with the latest figure at 224.71% for Q2 2020.

  • For Q2 2020, EBT Margin rose 14709.0% year-over-year to 224.71%; the TTM value through Jan 2021 reached 1252.22%, down 90462.0%, while the annual FY2025 figure was 1584.17%, 183745.0% up from the prior year.
  • EBT Margin for Q2 2020 was 224.71% at KalVista Pharmaceuticals, up from 783.26% in the prior quarter.
  • Across five years, EBT Margin topped out at 60.0% in Q2 2018 and bottomed at 5678.12% in Q3 2017.
  • The 5-year median for EBT Margin is 319.09% (2019), against an average of 1189.03%.
  • The largest annual shift saw EBT Margin crashed -515443bps in 2017 before it soared 549200bps in 2018.
  • A 5-year view of EBT Margin shows it stood at 2038.07% in 2016, then skyrocketed by 74bps to 526.71% in 2017, then surged by 84bps to 83.85% in 2018, then plummeted by -167bps to 224.08% in 2019, then decreased by 0bps to 224.71% in 2020.
  • Per Business Quant, the three most recent readings for KALV's EBT Margin are 224.71% (Q2 2020), 783.26% (Q1 2020), and 224.08% (Q4 2019).